[From the angiogenic response to ischemia to the validation of the concept of "therapeutic angiogenesis"].
The object of this review is to assess the importance of angiogenesis in cardiovascular physiology and to review the new therapeutic approach which have opened up in this field. The authors report: 1) general information about growth factors implicated in angiotensin (fibroblast growth factor, vascular endothelial growth factor, scatter factor). 2) data obtained from embryo studies which have confirmed the relative rôle of certain intermediary molecules, especially vascular endothelial growth factor in vascular formation. 3) results of animal model experiments of chronic ischaemia and 4) the therapeutic possibilities that these studies suggest and the preliminary results of human applications.
Van Belle
E
E
Departement de cardiologie B, Hôpital cardiologique, Lille.
Bauters
C
C
Bertrand
M E
ME
D000804:Angiotensin II / Q000494:pharmacology / Q000502:physiology; D000818:Animals; D002318:Cardiovascular Diseases / Q000628:therapy*; D004195:Disease Models, Animal; D016228:Endothelial Growth Factors / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D008222:Lymphokines / Q000494:pharmacology / Q000502:physiology; D017202:Myocardial Ischemia / Q000503:physiopathology*; D018919:Neovascularization, Physiologic; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000804:Angiotensin II